Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer

• Publication date

  2011-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.25526PMID 20960500PMCID PMC3025267
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Therapies for the Treatment of Small-Cell Lung Cancer

  2012cited by this paper
• Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

  2010cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer.

  2009cited by this paper
• Prognostic factors differ by tumor stage for small cell lung cancer

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

  2009cited by this paper
• Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

  2009cited by this paper
• Stable Disease Is a Valid End Point in Clinical Trials

  2009cited by this paper
• Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials

  2008cited by this paper
• End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

  2007cited by this paper
• Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.

  2007cited by this paper
• Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Phase II NCCTG Trial of Oral Topotecan and Paclitaxel With G-CSF (Filgrastim) Support in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

  2006cited by this paper
• Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer.

  2004cited by this paper
• Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

  2004cited by this paper
• Randomized Phase II Study of Daily Versus Continuous-Infusion Schedules of Topotecan in the Treatment of Extensive-Stage Small Cell Lung Cancers

  2003cited by this paper
• Judging new markers by their ability to improve predictive accuracy.

  2003cited by this paper
• Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive‐stage small cell lung carcinoma

  2003cited by this paper
• Validation of surrogate end points in multiple randomized clinical trials with failure time end points

  2001cited by this paper
• The validation of surrogate endpoints in meta-analyses of randomized experiments.

  2000cited by this paper
• Response rates, survival, and chemotherapy trials.

  2000cited by this paper
• Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group.

  1999cited by this paper
• Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.

  1996cited by this paper
• Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer.

  1996cited by this paper
• Measurable or assessable disease in lung cancer trials: does it matter?

  1994cited by this paper
• Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial.

  1994cited by this paper
• Cancer statistics

  1989cited by this paper
• Criteria of tumor response used in clinical trials of chemotherapy.

  1985cited by this paper
• Regression modelling strategies for improved prognostic prediction.

  1984cited by this paper
• Improving the efficiency of clinical trials: a medical perspective.

  1984cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer.

  2026cites this paper
• Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials

  2025cites this paper
• Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer.

  2025cites this paper
• Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes.

  2025cites this paper
• Lineage plasticity and histological transformation: tumor histology as a spectrum

  2025cites this paper
• Evaluation of progression-free survival as a surrogate endpoint for overall survival in small cell lung cancer: a systematic review

  2025influential citation
• Optimizing End Points for Phase III Cancer Trials.

  2024cites this paper
• Association of Plasma Nestin With Response to Immune Checkpoint Inhibitors Combined With Chemotherapy in Extensive-stage Small-cell Lung Cancer: A Pilot Study

  2024cites this paper
• Development and validation of nomograms for predicting survival in small cell lung cancer patients with brain metastases: a SEER population-based analysis.

  2024cites this paper
• Outcomes and Prognostic Factors of Extensive Stage Small Cell Lung Cancer: A Retrospective Study

  2023cites this paper
• Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis

  2023cites this paper
• Lung Large Cell Neuroendocrine Carcinoma: A Population-Based Retrospective Cohort Study

  2023cites this paper
• Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review

  2023cites this paper
• Prediction of Efficacy of Immunotherapy for Extensive Stage Small Cell Lung Cancer

  2023cites this paper
• ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors

  2022cites this paper
• Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2022cites this paper
• The 6-min walk test as a primary end-point in interstitial lung disease

  2022cites this paper
• Real-world evidence for immunotherapy in the first line setting in small cell lung cancer.

  2022cites this paper
• Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types

  2022cites this paper
• Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival

  2022cites this paper
• MicroRNA signature of small‐cell lung cancer after treatment failure: impact on oncogenic targets by miR‐30a‐3p control

  2022cites this paper
• Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy

  2022cites this paper
• Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer

  2021cites this paper
• A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study

  2021cites this paper
• Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review

  2021cites this paper
• Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis

  2021cites this paper
• Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.

  2021cites this paper
• Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes

  2021cites this paper
• FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.

  2021cites this paper
• Concordance index: Surrogacy of progression-free survival for overall survival.

  2021cites this paper
• Surrogate endpoint evaluation using data from one large global randomized controlled trial

  2021cites this paper
• A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer

  2020cites this paper
• Lineage plasticity in cancer: a shared pathway of therapeutic resistance

  2020cites this paper
• Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort

  2020cites this paper
• Cancer therapy: Attempt cure or manage drug resistance?

  2020cites this paper
• Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.

  2020cites this paper
• Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer

  2020cites this paper
• The combination of pretreatment PNI and NSE enhances prognosis predicting value of SCLC.

  2020cites this paper
• Paraneoplastic Focal Outer Retinitis and Optic Neuropathy in a Patient with Small Cell Lung Carcinoma and Anti-CRMP5, Anti-HU and Anti-Amphiphysin Antibodies

  2020cites this paper
• The combination of pretreatment prognostic nutritional index and neuron‐specific enolase enhances prognosis predicting value of small cell lung cancer

  2020cites this paper
• Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer

  2019cites this paper
• Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network

  2019cites this paper
• Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors

  2019cites this paper
• Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.

  2019cites this paper
• Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors

  2018cites this paper
• Immune checkpoint inhibitors and small cell lung cancer: what's new?

  2018cites this paper
• Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.

  2018cites this paper
• Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis

  2018cites this paper
• Is prophylactic cranial irradiation indicated for patients with extensive-stage small cell lung cancer with a complete response to first-line treatment?

  2018cites this paper
• Tumor mutation burden as emerging biomarker in non-small cell lung cancer and beyond

  2018cites this paper
• The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer

  2018cites this paper
• Clinical significance of post‐progression survival in lung cancer

  2017cites this paper
• Surrogate endpoints for overall survival in lung cancer trials: a review

  2017cites this paper
• Another disappointing result, but how good is it?

  2017cites this paper
• Staging in Patients with Small-Cell Lung Carcinoma; PET-CT versus Standard Staging Procedures

  2017cites this paper
• Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials

  2017cites this paper
• Evidenzbasiertes Vorgehen beim kleinzelligen Lungenkarzinom

  2017cites this paper
• Progression‐Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta‐Analysis of 37 Trials

  2017cites this paper
• Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study

  2017cites this paper
• Phase 1/2 Study of the CD56‐Targeting Antibody‐Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small‐Cell Lung Cancer Patients With Extensive‐Stage Disease

  2017cites this paper
• Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

  2017cites this paper
• Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.

  2017cites this paper
• Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example

  2017cites this paper
• Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide

  2016cites this paper
• Should patients with laryngeal small cell neuroendocrine carcinoma receive prophylactic cranial irradiation?

  2016cites this paper
• Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer

  2016cites this paper
• [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience

  2016cites this paper
• Treatment for small cell lung cancer, where are we now?-a review.

  2016cites this paper
• Survival analyses in lung cancer.

  2016cites this paper
• Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer.

  2016cites this paper
• Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.

  2016cites this paper
• Clinical impact of post‐progression survival on overall survival in elderly patients with extensive disease small‐cell lung cancer

  2016cites this paper
• Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)

  2016cites this paper
• Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy

  2016cites this paper
• Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer.

  2016cites this paper
• Clinical trial end points relevant to patients and society for rare cancers

  2015cites this paper
• Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer

  2015cites this paper
• Correction: Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2015cites this paper
• Modified one-day etoposide and cisplatin combination for previously untreated extensive-disease small-cell lung cancer: A retrospective evaluation of 36 cases.

  2015cites this paper
• Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer

  2015cites this paper
• Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2015cites this paper
• Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard

  2015cites this paper
• Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

  2015cites this paper
• Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer

  2015cites this paper
• Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres

  2015cites this paper
• Small cell lung cancer in never-smokers

  2015cites this paper
• Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

  2015influential citation
• Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer.

  2015cites this paper
• Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.

  2015cites this paper
• Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points

  2015cites this paper
• Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

  2015cites this paper
• The Globalization of Cooperative Groups.

  2015cites this paper
• Title DISEASE CONTROL RATE AT 8 WEEKS PREDICTS SUBSEQUENT SURVIVAL IN PLATINUM-TREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER ( ES-SCLC ) : A PATIENT LEVEL ANALYSIS OF SWOG TRIALS Permalink

  2015cites this paper
• The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

  2015cites this paper
• Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

  2015cites this paper
• Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy

  2014cites this paper
• Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

  2014cites this paper
• Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.

  2014cites this paper
• Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.

  2014cites this paper
• Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.

  2014cites this paper